{"version":"1.0","type":"rich","provider_name":"Tech & Business","provider_url":"https://techandbusiness.org","title":"Novartis agrees to acquire pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics","author_name":"T&B Newswire · Tech & Business","thumbnail_url":"https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;text-transform:uppercase;\">T&B NEWSWIRE · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/WMYow9Ig064KslncDNxrls\" style=\"color:#fff;text-decoration:none;\">Novartis agrees to acquire pan-mutant-selective PI3Kα inhibitor from Synnovation Therapeutics</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Novartis has entered into an agreement with Synnovation Therapeutics to acquire SNV4818, a pan-mutant-selective PI3Kα inhibitor. The asset is being developed for patients with hormone receptor positiv...</p>\n    </blockquote>"}